Tarsus Pharmaceuticals, Inc.
TARS · NASDAQ
12/31/2024 | 12/31/2023 | 12/31/2022 | 12/31/2021 | |
|---|---|---|---|---|
| Market Cap | $2,082,189 | $595,011 | $360,925 | $462,467 |
| - Cash | $94,819 | $224,947 | $71,660 | $171,332 |
| + Debt | $72,453 | $31,732 | $20,155 | $1,891 |
| Enterprise Value | $2,059,823 | $401,796 | $309,420 | $293,026 |
| Revenue | $182,953 | $17,447 | $25,816 | $57,027 |
| % Growth | 948.6% | -32.4% | -54.7% | – |
| Gross Profit | $170,127 | $15,854 | $24,861 | $54,952 |
| % Margin | 93% | 90.9% | 96.3% | 96.4% |
| EBITDA | -$106,480 | -$131,670 | -$59,705 | -$13,460 |
| % Margin | -58.2% | -754.7% | -231.3% | -23.6% |
| Net Income | -$115,554 | -$135,893 | -$62,091 | -$13,827 |
| % Margin | -63.2% | -778.9% | -240.5% | -24.2% |
| EPS Diluted | -3.07 | -4.62 | -2.52 | -0.67 |
| % Growth | 33.5% | -83.3% | -276.1% | – |
| Operating Cash Flow | -$83,027 | -$117,493 | -$49,030 | $3,748 |
| Capital Expenditures | -$1,567 | -$5,502 | -$506 | -$586 |
| Free Cash Flow | -$84,594 | -$122,995 | -$49,536 | $3,162 |